(thirdQuint)A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

 This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer.

 The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC.

 The study will evaluate progression-free survival between the two arms.

 A total of 154 patients will be enrolled.

.

 A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)@highlight

This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer.

 The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC.

